Pathogenesis of Thrombotic Thrombocytopenic Purpura: ADAMTS13 Deficiency and Beyond

ABSTRACT

Thrombotic thrombocytopenic purpura (TTP) is characterized by the systemic deposition of platelet thrombi with abundance of von Willebrand factor (vWF) in the arterioles and capillaries. Recently, vWF protease (ADAMTS13) activity was found to be severely deficient in hereditary TTP as well as acquired idiopathic TTP. Homozygous or compound heterozygous mutations of ADAMTS13 gene were demonstrated in hereditary TTP. Autoantibodies against ADAMTS13 were present in majority of patients with idiopathic TTP and ticlopidine- and clopidogrel-associated TTP. The deficiency of ADAMTS13 leaves unchecked the hyperadhesive vWF unfolded under high shear stress in the microvessels, resulting in the formation of platelet thrombi, which in turn causes TTP. ADAMTS13 activity is usually normal in hemolytic uremic syndrome. Approximately 0 to 67% of idiopathic TTP patients reported may not be severely deficient of ADAMTS13. Therefore, acquired TTP is not caused by ADAMTS13 deficiency alone and may be triggered by certain stimuli that possibly cause autoimmune reactivity to ADAMTS13, and also induce platelet aggregation either dependent on or independent of vWF, and/or vascular injury, to account for variable clinical and laboratory presentations. Plasma samples from TTP patients have been shown to induce endothelial cell apoptosis and activation. Platelet aggregating factors independent of vWF purified from the plasma of a subset of TTP patients have been reported and shown to be inhibited by normal plasma and immunoglobulin G purified from normal plasma. Defective fibrinolysis and abnormal natural coagulation inhibitors may enhance the thrombi formation in the microcirculation.

KEYWORDS

Thrombotic thrombocytopenic purpura (TTP) - ADAMTS13 - autoantibodies - platelet aggregation - vascular injury

REFERENCES

• 1 Moschcowitz E. Hyaline thrombosis of the terminal arterioles and capillaries: a hitherto undescribed disease.  Proc N Y Pathol Soc. 1924;  24 21-24
• 2 Gore I. Disseminated arteriolar and capillary platelet thrombosis; a morphologic study of its histogenesis.  Am J Pathol. 1950;  26(1) 155-175
• 3 Feldman J D, Mardiney M R, Unanue E R et al.. The vascular pathology of thrombotic thrombocytopenic purpura: An immunohistochemical and ultrastructural study.  Lab Invest. 1966;  15 927-946
• 4 Asada Y, Sumiyoshi A, Hayashi T et al.. Immunohistochemistry of vascular lesions in thrombotic thrombocytopenic purpura, with special reference to factor VIII related antigen.  Thromb Res. 1985;  38 469-479
• 5 Schulman I, Pierce M, Lukens A, Currimbhoy Z. Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency.  Blood. 1960;  16 943-957
• 6 Upshaw J D. Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia.  N Engl J Med. 1978;  298 1350-1352
• 7 Moake J L, Rudy C K, Troll J H. Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura.  N Engl J Med. 1982;  307 1432-1435
• 8 Furlan M, Robles R, Solenthaler M et al.. Deficient activity of von Willebrand factor-cleaving protease in chronic relapsing thrombotic thrombocytopenic purpura.  Blood. 1997;  89 3097-3103
• 9 Furlan M, Robles R, Galbusera M et al.. Von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  N Engl J Med. 1998;  339 1578-1584
• 10 Tsai H M, Lian E C. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.  N Engl J Med. 1998;  339 1585-1594
• 11 Levy G G, Nichols W C, Lian E C et al.. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenia purpura.  Nature. 2001;  413(6855) 488-494
• 12 Fujikawa K, Suzuki H, McMullen B, Chung D. Purification of human von Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family.  Blood. 2001;  98 1662-1666
• 13 Gerritsen H E, Robles R, Lammle B, Furlan M. Partial amino acid sequence of purified von Willebrand factor-cleaving protease.  Blood. 2001;  98 1654-1661
• 14 Zheng X, Chung D, Takayama T K et al.. Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura.  J Biol Chem. 2001;  276 41059-41063
• 15 Moake J L, Rudy C K, Troll J H et al.. von Willebrand factor abnormalities and endothelial cell perturbation in a patient with acute thrombotic thrombocytopenic purpura.  Am J Med Sci. 1986;  291(1) 47-50
• 16 Mannucci P M, Lombardi R, Lattuada A et al.. Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome.  Blood. 1989;  74(3) 978-988
• 17 Moake J L, McPherson P D. Abnormalities of von Willebrand factor multimers in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome.  Am J Med. 1989;  87(3N) 9N-15N
• 18 Galbusera M, Benigni A, Paris S et al.. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.  J Am Soc Nephrol. 1999;  10(6) 1234-1241
• 19 Veyradier A, Obert B, Houllier A, Meyer D, Girma J P. Specific von Willebrand factor-cleaving protease in thrombotic microangiopathies: a study of 111 cases.  Blood. 2001;  98(6) 1765-1772
• 20 Wagner D D. Storage and secretion of von Willebrand factor. In: Ruggeri ZM, Zimmerman TS Coagulation and Bleeding Disorders: The Role of Factor VIII and von Willebrand Factor. New York and Basel; Marcel Dekker 1989: 161-180
• 21 Wagner D D. The Weibel-Palade body: the storage granule for von Willebrand factor and P-selectin.  Thromb Haemost. 1993;  70 105-110
• 22 Ruggeri Z M, Dent J A, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood.  Blood. 1999;  94 172-178
• 23 Berkowitz S D, Dent J, Roberts J et al.. Epitope mapping of the von Willebrand factor subunit distinguishes fragments present in normal and type IIA von Willebrand disease from those generated by plasmin.  J Clin Invest. 1987;  79(2) 524-531
• 24 Dent J A, Berkowitz S D, Ware J, Kasper C K, Ruggeri Z M. Identification of a cleavage site directing the immunochemical detection of molecular abnormalities in type IIA von Willebrand factor.  Proc Natl Acad Sci USA. 1990;  87 6306-6310
• 25 Tsai H M. Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion.  Blood. 1996;  87 4235-4244
• 26 Furlan M, Robles R, Lammie B. Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis.  Blood. 1996;  87 4223-4234
• 27 Goto S, Ikeda Y, Saldivar E, Ruggeri Z M. Distinct mechanisms of platelet aggregation as a consequence of different shearing flow conditions.  J Clin Invest. 1998;  101 479-486
• 28 Siedlecki C A, Lestini B J, Kottke-Marchant K et al.. Shear-dependent changes in the three-dimensional structure of human von Willebrand factor.  Blood. 1996;  88 2939-2950
• 29 Dong J F, Moake J L, Bernardo A et al.. ADAMTS-13 metalloprotease interacts with the endothelial cell-derived ultra-large von Willebrand factor.  J Biol Chem. 2003;  278(32) 29633-29639
• 30 Ajzenberg N, Denis C V, Veyradier A et al.. Complete defect in vWF-cleaving protease activity associated with increased shear-induced platelet aggregation in thrombotic microangiopathy.  Thromb Haemost. 2002;  87(5) 808-811
• 31 Yagi H, Konno M, Kinoshita S et al.. Plasma of patients with Upshaw-Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress.  Br J Haematol. 2001;  115(4) 991-997
• 32 Lopez J A, Dong J F. Cleavage of von Willbrand factor by ADAMTS-13 on enodothelial cells.  Semin Hematol. 2004;  41 15-23
• 33 Federici A B, Bader R, Pagani S et al.. Binding of von Willebrand factor to glycoproteins Ib and IIb/IIIa complex: affinity is related to multimeric size.  Br J Haematol. 1989;  73(1) 93-99
• 34 Tsai H M. Von Willebrand factor. ADAMTS 13 and thrombotic thrombocytopenic purpura.  J Mol Med. 2002;  80 639-647
• 35 Levy G G, Motto D G, Ginsburg D. ADAMTS13 turns 3.  Blood. 2005;  106 11-17
• 36 Kokame K, Matsumoto M, Soejima K et al.. Mutations and common polymorphisms in ADAMTS13 gene responsible for von Willebrand factor-cleaving protease activity.  Proc Natl Acad Sci USA. 2002;  99 11902-11907
• 37 Zhou W, Inada M, Lee T P et al.. ADAMTS13 is expressed in hepatic stellate cells.  Lab Invest. 2005;  85(6) 780-788
• 38 Matsumoto M, Kokame K, Soejima K et al.. Molecular characterization of ADAMTS13 gene mutations in Japanese patients with Upshaw-Schulman syndrome.  Blood. 2004;  103 1305-1310
• 39 Assink K, Schiphorst R, Allford S et al.. Mutation analysis and clinical implications of von Willebrand factor-cleaving protease deficiency.  Kidney Int. 2003;  63 1995-1999
• 40 Uchida T, Wada H, Mizutani M et al.. Identification of novel mutations in ADAMTS13 in an adult patient with congenital thrombotic thrombocytopenic purpura.  Blood. 2004;  104 2081-2083
• 41 Veyradier A, Lavergne J M, Ribba A S et al.. Ten candidate ADAMTS13 mutations in six French families with congenital thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome).  J Thromb Haemost. 2004;  2 424-429
• 42 Pimanda J E, Maekawa A, Wind T et al.. Congenital thrombotic thrombocytopenic purpura in association with a mutation in the second CUB domain of ADAMTS13.  Blood. 2004;  103 627-629
• 43 Savasan S, Lee S K, Ginsburg D, Tsai H M. ADAMTS13 gene mutation in congenital thrombotic thrombocytopenic purpura with previously reported normal vWF cleaving protease activity.  Blood. 2003;  101 4449-4451
• 44 Schneppenheim R, Budde U, Oyen F et al.. von Willebrand factor cleaving protease and ADAMTS13 mutations in childhood TTP.  Blood. 2003;  101 1845-1850
• 45 Licht C, Stapenhorst L, Simon T, Budde U, Schneppenheim R, Hoppe B. Two novel ADAMTS13 gene mutations in thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome (TTP/HUS).  Kidney Int. 2004;  66 955-958
• 46 Vesely S K, George J N, Lämmle B et al.. ADAMTS13 activity in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: relation to presenting features and clinical outcomes in a prospective cohort of 142 patients.  Blood. 2003;  102 60-68
• 47 Peyvandi F, Ferrari S, Lavoretano S, Canciani M T, Mannucci P M. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 2004;  127(4) 433-439
• 48 Matsumoto M, Yagi H, Ishizashi H, Wada H, Fujimura Y. The Japanese experience with thrombotic thrombocytopenic purpura-hemolytic uremic syndrome.  Semin Hematol. 2004;  41(1) 68-74
• 49 Rieger M, Mannucci P M, Hovinga J A et al.. ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases.  Blood. 2005;  106(4) 1262-1267
• 50 Soejima K, Matsumoto M, Kokame K et al.. ADAMTS-13 cysteine-rich/spacer domains are functionally essential for von Willebrand factor cleavage.  Blood. 2003;  102 3232-3237
• 51 Klaus C, Plaimauer B, Studt J-D et al.. Epitope mapping of ADAMTS13 autoantibodies in acquired thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4514-4519
• 52 Scheiflinger F, Knobl P, Trattner B et al.. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.  Blood. 2003;  102(9) 3241-3243
• 53 Albert L J, Inman R D. Mechanisms of Disease: Molecular Mimicry and Autoimmunity.  N Engl J Med. 1999;  341 2068-2074
• 54 Davidson A, Diamond B. Advances in immunology: autoimmune diseases.  N Engl J Med. 2001;  345 340-350
• 55 Tsai H M, Rice L, Sarode R, Chow T W, Moake J L. Antibody inhibitors to von Willebrand factor metalloproteinase and increased binding of von Willebrand factor to platelets in ticlopidine-associated thrombotic thrombocytopenic purpura.  Ann Intern Med. 2000;  132(10) 794-799
• 56 Bennett C L, Connors J M, Carwile J M et al.. Thrombotic thrombocytopenic purpura associated with clopidogrel.  N Engl J Med. 2000;  342(24) 1773-1777
• 57 Schults D R, Arnold P I, Ji W et al.. AntiCD36 autoantibodies in thrombotic thrombocytopenic purpura and other thrombotic disorders: identification of an 85 KD form of CD36 as a target antigen.  Br J Haematol. 1998;  103 849-857
• 58 Wight J F, Wang H, Horstein A et al.. Characterization of platelet glycoproteins and platelet/endothelial cell antibodies in patients with thrombotic thrombocytopenic purpura.  Br J Haematol. 1999;  107 546-555
• 59 Galbusera M, Benigni A, Paris S et al.. Unrecognized pattern of von Willebrand factor abnormalities in hemolytic uremic syndrome and thrombotic thrombocytopenic purpura.  J Am Soc Nephrol. 1999;  10(6) 1234-1241
• 60 Motto D, Zhang W, Zhu G et al.. Additional environmental and/or genetic factors are required to trigger TTP in ADAMTS13-deficient mice.  Blood. 2004;  104 258
• 61 Hovinga J AK, Studt J-D, Alberio L, von Lammle B. Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience.  Semin Hematol. 2004;  41 75-82
• 62 Zheng X L, Kaufman R M, Goodnough L T, Sadler J E. Effect of plasma exchange on plasma ADAMTS13 metalloprotease activity, inhibitor level, and clinical outcome in patients with idiopathic and non-idiopathic thrombotic thrombocytopenic purpura.  Blood. 2004;  103 4043-4049
• 63 Bohm M, Betz C, Miesbach W et al.. The course of ADAMTS13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exachange and vicnrsitine.  Br J Haematol. 2005;  129 644-652
• 64 Altschule M D. The Kidney: Medical and Surgical Disease. New York; Grume & Stratton 1953: 458
• 65 Mitra D, Jaffe E A, Weksler B et al.. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.  Blood. 1997;  89 1224-1234
• 66 Dang C T, Magid M S, Weksler B et al.. Enhanced endothelial cell apoptosis in splenic tissues of patients with thrombotic thrombocytopenic purpura.  Blood. 1999;  93 1264-1270
• 67 Wu X W, Li Z Y, Lian E C. Plasma from a patient with thrombotic thrombocytopenic purpura induces endothelial cell apoptosis and platelet aggregation.  Thromb Res. 1999;  93(2) 79-87
• 68 Jimennez J J, Ji W, Mauro L M et al.. Endothelial microparticles released in thrombotic thrombocytopenic purpura express von Willbrand factor and markers of endothelial activation.  Br J Haematol. 2003;  123 896-902
• 69 Lian EC- Y, Harkness D R, Byrnes J J, Wallach H, Nunez R. The presence of a platelet aggregating factors in the plasma of patients with thrombotic thrombocytopenic purpura and its inhibition by normal plasma.  Blood. 1979;  53 333-338
• 70 Suehiro A, Yoshimoto H, Higasa S, Kakishita E. Platelet aggregating activity of plasma in patients with thrombotic thrombocytopenic purpura evaluated by a particle counting method using light scattering.  Int J Hematol. 1999;  70 40-46
• 71 Ahn Y S, Jy W, Kolodny L et al.. Activated platelet aggregates in thrombotic thrombocytopenic purpura: decrease with plasma infusions and normalization in remission.  Br J Haematol. 1996;  95 408-415
• 72 Lian EC- Y, Mu P TK, Siddiqui F A, Chiu A Y, Chiu L L. Inhibition of aggregating activity in thrombotic thrombocytopenic purpura plasma by normal adult immunoglobulin G.  J Clin Invest. 1984;  73 548-555
• 73 Siddiqui F A, Lian E CY. Platelet aggregation protein p37 from a thrombotic purpura.  J Clin Invest. 1986;  76 1330-1337
• 74 Lian EC-Y. The role of increased platelet aggregation in TTP.  Semin Thromb Hemost. 1980;  6 401-415
• 75 Chen S-H, Lian EC-Y, Zhang X, Zhan M X. Purification and some properties of platelet aggregating protein (PAP) from the plasma of a patient with thrombotic thrombocytopenic purpura.  Natl Med J China. 1989;  69 382-384
• 76 Kwaan H C. The pathogenesis of thrombotic thrombocytopenic purpura.  Semin Thromb Hemost. 1979;  5(3) 84-98
• 77 Glas-Greenwalt P, Hall J M, Panke T W et al.. Fibrinolysis in health and disease: abnormal levels of plasminogen activator, plasminogen activator inhibitor, and protein C in thrombotic thrombocytopenic purpura.  J Lab Clin Med. 1985;  108 415-422
• 78 Lian EC-Y, Nunez R L, Harkness D R. In vivo and in vitro effects of thrombin and plasmin on human Factor VIII (AHF).  Am J Hematol. 1976;  1 481-491
• 79 Hamilton K K, Fretto L J, Grierson D S, McKee P A. Effects of plasmin on von Willebrand factor multimers. Degradation in vitro and stimulation of release in vivo.  J Clin Invest. 1985;  76(1) 261-270
• 80 Kunicki T J, Montgomery R R, Schullek J. Cleavage of human von Willebrand factor by platelet calcium-activated protease.  Blood. 1985;  65(2) 352-356
• 81 Jelenska M, Kopec M, Sopata I et al.. Fibrinogen does not protect von Willebrand factor against proteolysis by human cathepsin G.  Thromb Res. 1991;  61(4) 433-440